Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Proteome Sciences plc (PRM.L)
Cobham, ENG, GB
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also offers top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, as well as to academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -24.53% | -3.45% | -6.67% | -22.22% | -13.04% | -44.00% | -58.08% | -70.46% | -82.17% | -91.82% | -99.09% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%-23.1% Q4'25: +4.5% (vs Q4'23)
-
EPS growth Medical - Specialties: +10.1%+9.6% Q4'25: +49.2% (vs Q4'23)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-28.9% Q4'25: +42.8% (vs Q4'23)
-
EBIT margin Medical - Specialties: +12.6%-71.0% Q4'25: -55.0% (vs Q4'23)
-
ROIC Medical - Specialties: +6.6%-48.9% Q4'25: -46.4% (vs Q4'23)
-
Share dilution Medical - Specialties: 0.0%+0.0% ★ Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×-9.06× Q4'25: -7.41× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.88M
est: 1.90M (-0.9%)
|
2.74M
est: 2.74M (+0.1%)
|
3.38M
est: 3.20M (+5.6%)
|
3.05M
est: 3.00M (+1.6%)
|
4.63M
est: 3.80M (+21.9%)
|
4.89M
est: 1.90M (+157.2%)
|
3.76M
est: 2.74M (+37.1%)
|
3.20M
3.20M – 3.20M
+16.8% YoY
|
3.00M
3.00M – 3.00M
-6.3% YoY
|
3.80M
3.80M – 3.80M
+26.7% YoY
|
| EBITDA |
-2.70M
est: -203.7K (-1,226.2%)
|
-2.12M
est: -293.7K (-622.5%)
|
-1.46M
est: -343.0K (-326.8%)
|
-1.14M
est: -321.6K (-253.9%)
|
368.0K
est: -407.3K (+190.3%)
|
-1.44M
est: -216.4K (-564.2%)
|
-1.74M
est: -312.0K (-457.7%)
|
-364.4K
-364.4K – -364.4K
-16.8% YoY
|
-341.6K
-341.6K – -341.6K
+6.2% YoY
|
-432.7K
-432.7K – -432.7K
-26.7% YoY
|
| EBIT |
-3.10M
est: -305.3K (-913.9%)
|
-2.68M
est: -440.3K (-507.5%)
|
-1.80M
est: -514.3K (-249.2%)
|
-1.37M
est: -482.1K (-183.5%)
|
279.0K
est: -610.7K (+145.7%)
|
-2.27M
est: -446.9K (-408.8%)
|
-2.67M
est: -644.5K (-313.7%)
|
-752.7K
-752.7K – -752.7K
-16.8% YoY
|
-705.6K
-705.6K – -705.6K
+6.3% YoY
|
-893.8K
-893.8K – -893.8K
-26.7% YoY
|
| Net Income |
-2.72M
est: -4.43M (+38.6%)
|
-2.28M
est: -2.36M (+3.4%)
|
-2.50M
est: -1.48M (-69.2%)
|
-1.31M
est: -2.07M (+36.5%)
|
149.0K
est: -1.18M (+112.6%)
|
-3.41M
est: -4.43M (+23.1%)
|
-3.06M
est: -2.36M (-29.6%)
|
-1.48M
-1.48M – -1.48M
+37.5% YoY
|
-2.07M
-2.07M – -2.07M
-40.0% YoY
|
-1.18M
-1.18M – -1.18M
+42.9% YoY
|
| SGA |
2.94M
est: 482.2K (+509.5%)
|
3.15M
est: 695.3K (+352.7%)
|
3.56M
est: 812.1K (+337.8%)
|
2.80M
est: 761.3K (+267.1%)
|
2.30M
est: 964.3K (+138.3%)
|
1.50M
est: 737.0K (+103.7%)
|
1.66M
est: 1.06M (+56.1%)
|
1.24M
1.24M – 1.24M
+16.8% YoY
|
1.16M
1.16M – 1.16M
-6.2% YoY
|
1.47M
1.47M – 1.47M
+26.7% YoY
|
| EPS |
-0.01
est: -0.02 (+18.0%)
|
-0.01
est: -0.01 (-20.0%)
|
-0.01
est: -0.01 (-70.0%)
|
0.00
est: -0.01 (+37.1%)
|
0.00
est: 0.00 (+112.5%)
|
-0.01
est: -0.02 (+23.3%)
|
-0.01
est: -0.01 (-30.0%)
|
-0.01
-0.01 – -0.01
+37.5% YoY
|
-0.01
-0.01 – -0.01
-40.0% YoY
|
0.00
0.00 – 0.00
+42.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ian H. Pike | Chief Scientific Officer & Executive Director | 182.0K | — |
| Richard Paul Dennis | Chief Commercial Officer & Executive Director | 162.0K | male |
| Christopher Donovan James Pearce | Executive Chairman | 56.8K | male |
| Victoria Birse | Company Secretary | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PRM.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
